Abstract
With the discovery of COX, pain has not been treated in a relentless manner. Numbers of drugs with fewer side effects were discovered and are used successfully for treatment of pain. With new research coming into being since the discovery of COX, it was established that COX can be targeted not only for treatment of pain but for curing various diseases like cancer, Alzheimer’s, Parkinson’s disease, Glaucoma etc. With the sighting of COX-3, another isoform of COX, new diseases are being targeted for better treatment.
Keywords: Anticancer, COX, COX-3, cyclooxygenase, inflammation, NSAIDs, pain.
Graphical Abstract
Inflammation & Allergy - Drug Targets (Discontinued)
Title:The Ambidextrous Cyclooxygenase: An Enduring Target
Volume: 13 Issue: 6
Author(s): Mayank Bapna and Lalit Singh Chauhan
Affiliation:
Keywords: Anticancer, COX, COX-3, cyclooxygenase, inflammation, NSAIDs, pain.
Abstract: With the discovery of COX, pain has not been treated in a relentless manner. Numbers of drugs with fewer side effects were discovered and are used successfully for treatment of pain. With new research coming into being since the discovery of COX, it was established that COX can be targeted not only for treatment of pain but for curing various diseases like cancer, Alzheimer’s, Parkinson’s disease, Glaucoma etc. With the sighting of COX-3, another isoform of COX, new diseases are being targeted for better treatment.
Export Options
About this article
Cite this article as:
Bapna Mayank and Chauhan Singh Lalit, The Ambidextrous Cyclooxygenase: An Enduring Target, Inflammation & Allergy - Drug Targets (Discontinued) 2014; 13 (6) . https://dx.doi.org/10.2174/1871528114666150401105545
DOI https://dx.doi.org/10.2174/1871528114666150401105545 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy
Current Gene Therapy Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond
Current Cancer Drug Targets Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry Editorial [Hot Topic:Therapeutic Potential of Peptide Motifs - Part V (Executive Guest Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry Therapeutic Targets in Polycystic Liver Disease
Current Drug Targets Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Current Signal Transduction Therapy Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Stem Cell Guardians – Old and New Perspectives in LSC Biology
Current Drug Targets Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Development of Small-Molecule Inhibitors of Raf
Recent Patents on Anti-Infective Drug Discovery Research Progress of Exogenous Plant MiRNAs in Cross-Kingdom Regulation
Current Bioinformatics How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies